BR112022000710A2 - Vacina viral terapêutica - Google Patents
Vacina viral terapêuticaInfo
- Publication number
- BR112022000710A2 BR112022000710A2 BR112022000710A BR112022000710A BR112022000710A2 BR 112022000710 A2 BR112022000710 A2 BR 112022000710A2 BR 112022000710 A BR112022000710 A BR 112022000710A BR 112022000710 A BR112022000710 A BR 112022000710A BR 112022000710 A2 BR112022000710 A2 BR 112022000710A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral vaccine
- therapeutic viral
- viral
- receptor
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
vacina viral terapêutica. a presente invenção refere-se ao receptor fc viral ou fragmentos imunogênicos do mesmo para o tratamento de uma infecção viral em um indivíduo e, em particular, uma infecção pelo vírus do herpes. a presente invenção também se refere a um heterodímero que compreende ou consiste em um receptor fc de um vírus hsv ou um fragmento imunogênico do mesmo e um parceiro de ligação do referido vírus hsv ou um fragmento do mesmo, para uso em terapia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19187467 | 2019-07-21 | ||
EP19188219 | 2019-07-24 | ||
EP19191842 | 2019-08-14 | ||
PCT/EP2020/070462 WO2021013798A1 (en) | 2019-07-21 | 2020-07-20 | Therapeutic viral vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022000710A2 true BR112022000710A2 (pt) | 2022-03-22 |
Family
ID=71608016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022000710A BR112022000710A2 (pt) | 2019-07-21 | 2020-07-20 | Vacina viral terapêutica |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220273789A1 (pt) |
EP (1) | EP3999108A1 (pt) |
JP (1) | JP2022542032A (pt) |
KR (1) | KR20220035457A (pt) |
CN (1) | CN114206909A (pt) |
AU (1) | AU2020318680A1 (pt) |
BR (1) | BR112022000710A2 (pt) |
CA (1) | CA3146900A1 (pt) |
MX (1) | MX2022000879A (pt) |
WO (1) | WO2021013798A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3999093A4 (en) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | ANTIGEN GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
WO2023031858A1 (en) | 2021-09-01 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Plasmid dna purification methods |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
EP1284740B1 (en) | 2000-05-19 | 2008-05-21 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
ES2261453T3 (es) | 2000-08-04 | 2006-11-16 | Corixa Corporation | Nuevos compuestos inmunoefectores. |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
EP1482955B1 (en) | 2002-02-04 | 2013-12-25 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
KR100885008B1 (ko) | 2002-02-04 | 2009-02-20 | 코릭사 코포레이션 | 신규 면역효과기 화합물 |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
HUE026376T2 (en) | 2003-01-06 | 2016-05-30 | Corixa Corp | Certain aminoalkyl glucosamide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
AU2005245956B2 (en) | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
WO2006004878A1 (en) * | 2004-06-29 | 2006-01-12 | Wyeth | Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AU2007342345B9 (en) * | 2006-12-28 | 2013-09-12 | The Trustees Of The University Of Pennsylvania | Herpes Simplex Virus combined subunit vaccines and methods of use thereof |
US20130028925A1 (en) * | 2006-12-28 | 2013-01-31 | Harvey Friedman | Herpes simplex virus combined subunit vaccines and methods of use thereof |
US20110200582A1 (en) | 2009-12-23 | 2011-08-18 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
SI4005592T1 (sl) | 2010-07-06 | 2023-03-31 | Glaxosmithkline Biologicals S.A. | Virionom podobni dostavni delci za samopodvojene molekule RNA |
WO2012006380A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Cationic oil-in-water emulsions |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
WO2012031046A2 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
AU2011296062A1 (en) | 2010-08-31 | 2013-04-04 | Novartis Ag | Small liposomes for delivery of immunogen-encoding RNA |
SG10201605537XA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
JP6120839B2 (ja) | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
WO2013006834A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
DK2750707T3 (en) | 2011-08-31 | 2019-02-11 | Glaxosmithkline Biologicals Sa | PEGYLED LIPOSOMES FOR DELIVERING IMMUNOGEN-CODING RNA |
BR112015021791B1 (pt) | 2013-03-08 | 2022-08-30 | Novartis Ag | Compostos de lipídio catiônico e composições de lipídios e farmacêuticas |
EP3083579B1 (en) | 2013-12-19 | 2022-01-26 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
EP3872066A1 (en) | 2013-12-19 | 2021-09-01 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
WO2016037053A1 (en) | 2014-09-05 | 2016-03-10 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
BR112018008090A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
US11160860B2 (en) * | 2017-04-26 | 2021-11-02 | Merck Sharp & Dohme Corp. | HSV antigenic peptides and HSV protein vaccines |
-
2020
- 2020-07-20 JP JP2022503807A patent/JP2022542032A/ja active Pending
- 2020-07-20 BR BR112022000710A patent/BR112022000710A2/pt unknown
- 2020-07-20 AU AU2020318680A patent/AU2020318680A1/en active Pending
- 2020-07-20 US US17/627,998 patent/US20220273789A1/en active Pending
- 2020-07-20 KR KR1020227005154A patent/KR20220035457A/ko unknown
- 2020-07-20 MX MX2022000879A patent/MX2022000879A/es unknown
- 2020-07-20 WO PCT/EP2020/070462 patent/WO2021013798A1/en unknown
- 2020-07-20 CN CN202080053158.9A patent/CN114206909A/zh active Pending
- 2020-07-20 EP EP20740056.5A patent/EP3999108A1/en active Pending
- 2020-07-20 CA CA3146900A patent/CA3146900A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020318680A1 (en) | 2022-02-17 |
CN114206909A (zh) | 2022-03-18 |
KR20220035457A (ko) | 2022-03-22 |
JP2022542032A (ja) | 2022-09-29 |
US20220273789A1 (en) | 2022-09-01 |
MX2022000879A (es) | 2022-05-02 |
EP3999108A1 (en) | 2022-05-25 |
WO2021013798A1 (en) | 2021-01-28 |
CA3146900A1 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022000710A2 (pt) | Vacina viral terapêutica | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
BR112019000598A2 (pt) | rna para terapia de câncer | |
BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
WO2020028719A3 (en) | Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer | |
BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
BR112022016893A2 (pt) | Vacina contra a infecção do vírus da peste suína africana | |
BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas | |
BR112021024285A2 (pt) | Vetores aav com promotor da proteína zero da mielina e usos dos mesmos para tratar doenças associadas a células de schwann como doença de charcot marie tooth | |
MX2021012051A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos. | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
BR112022019207A2 (pt) | Composições de vacina para coronavírus e métodos de uso das mesmas | |
PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
BR132018069012E2 (pt) | uso de anticorpos policlonais humanos ou fragmentos destes, e, composição farmacêutica |